Page last updated: 2024-12-05

3-methyl-2-cyclohexen-1-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-methyl-2-cyclohexen-1-one: in a releaser significantly reduced trap catches and spruce beetle attacks on standing live spruce by 96 and 87%, respectively [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14511
CHEMBL ID3139347
CHEBI ID88428
SCHEMBL ID124901
MeSH IDM0448918

Synonyms (56)

Synonym
1193-18-6
methylcyclohexenone
3-methyl-2-cyclohexen-1-one
nsc43632
seudenone
3-methyl-2-cyclohexenone
nsc-43632
ai3-19937
brn 1560601
fema no. 3360
caswell no. 561ab
nsc 43632
epa pesticide chemical code 219700
einecs 214-769-7
3-methyl-2-cyclohexene-1-one
2-cyclohexen-1-one, 3-methyl-
3-methylcyclohex-2-en-1-one
inchi=1/c7h10o/c1-6-3-2-4-7(8)5-6/h5h,2-4h2,1h
GHL.PD_MITSCHER_LEG0.699 ,
3-methyl-2-cyclohexenone, 98%
3-methyl-2-cyclohexenone, >=98%, stabilized, fg
M1043
AKOS004909936
EN300-66416
786y352v9x ,
4-07-00-00130 (beilstein handbook reference)
unii-786y352v9x
NCGC00255585-01
tox21_302036
dtxcid6015186
cas-1193-18-6
dtxsid8035186 ,
3-methyl-cyclohex-2-en-1-one
FT-0603553
S10448
nutty cyclohexenone
3-methyl-2-cyclohexen-1-one [fhfi]
SCHEMBL124901
AKOS025243221
3-methylcyclohexenone
3-methylcyclohex-2-enone
3-methyl-cyclohexenone
CHEMBL3139347
chebi:88428 ,
J-004098
mfcd00001581
NS-00067
fema 3360
3-methyl-2-cyclohexenone-1
Q27160291
3-methyl-cyclohex-2-enone
manganese(ii)phosphatemonobasictetrahydrate
CS-0128362
SY011435
A934049
Z1042078386
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cyclic olefinThe inclusive term for any cyclic hydrocarbon having any number of double bonds.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency54.48270.000323.4451159.6830AID743065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (30.77)29.6817
2010's6 (46.15)24.3611
2020's3 (23.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.46 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]